29 43

Cited 0 times in

HBsAg-Negative, Anti-HBc-Negative Patients Still Have a Risk of Hepatitis B Virus-Related Hepatitis after Autologous Stem Cell Transplantation for Multiple Myeloma or Malignant Lymphoma

 Hyunsung Park  ;  Do Young Kim  ;  Soo-Jeong Kim  ;  Haerim Chung  ;  Hyunsoo Cho  ;  Ji Eun Jang  ;  June-Won Cheong  ;  Yoo Hong Min  ;  Jae-Woo Song  ;  Jin Seok Kim 
 Cancer Research and Treatment, Vol.50(4) : 1121-1129, 2018 
Journal Title
 Cancer Research and Treatment 
Issue Date
HBV-related hepatitis ; Hepatitis B core antibody ; Lymphoma ; Multiple myeloma ; Stem cell transplantation
PURPOSE: Although hepatitis B surface antigen (HBsAg)-negative, hepatitis B core antibody (anti-HBc)-negative patients are not considered to be at risk for hepatitis B virus (HBV)-related hepatitis, the actual risk remains to be elucidated. This study aimed to evaluate the risk of HBV-related hepatitis in HBsAg-negative, anti-HBc-negative patients receiving autologous stem cell transplantation (ASCT) for multiple myeloma (MM) or malignant lymphoma. Materials and Methods: We retrospectively reviewed data from 271 HBsAg-negative patients (161 anti-HBc-negative and 110 anti-HBc-positive at the time of ASCT) who received ASCT for MM or lymphoma. The risk of HBV-related hepatitis was analyzed according to the presence of anti-HBc. HBV serology results at the time of ASCT were compared with those at the time of diagnosis of MM or lymphoma. RESULTS: Three patients (two anti-HBc-negative MMs and one anti-HBc-positive MM) developed HBV-related hepatitis after ASCT. The rate of HBV-related hepatitis did not differ among patients with or without anti-HBc status (p=0.843). HBV-related hepatitis more frequently occurred in MM patients than in lymphoma patients (p=0.041). Overall, 9.1% of patients (16.7% with MM and 5.4% with lymphoma) who were HBsAg-negative and anti-HBc-positive at the time of diagnosis had lost anti-HBc positivity during chemotherapy prior to ASCT. CONCLUSION: Our data suggest that HBsAg-negative, anti-HBc-negative patients at the time of ASCT for MM or lymphoma still might be at a risk for HBV-related hepatitis.
Files in This Item:
T201804804.pdf.pdf Download
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Laboratory Medicine (진단검사의학교실) > 1. Journal Papers
Yonsei Authors
김도영(Kim, Do Young)
김수정(Kim, Soo Jeong) ORCID logo https://orcid.org/0000-0001-8859-3573
김진석(Kim, Jin Seok) ORCID logo https://orcid.org/0000-0001-8986-8436
민유홍(Min, Yoo Hong) ORCID logo https://orcid.org/0000-0001-8542-9583
박현성(Park, Hyeun Sung)
송재우(Song, Jae Woo) ORCID logo https://orcid.org/0000-0002-1877-5731
장지은(Jang, Ji Eun) ORCID logo https://orcid.org/0000-0001-8832-1412
정준원(Cheong, June-Won) ORCID logo https://orcid.org/0000-0002-1744-0921
정해림(Chung, Hae Rim) ORCID logo https://orcid.org/0000-0002-7926-9285
RIS (EndNote)
XLS (Excel)
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.